A study to compare two types of chemotherapy that is 3 plus 7 & AZA plus VEN for the treatment of a blood cancer called Acute Myeloid Leukemia
Not Applicable
- Conditions
- Health Condition 1: C929- Myeloid leukemia, unspecified
- Registration Number
- CTRI/2023/06/053981
- Lead Sponsor
- Dr Manju Sengar
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1- Newly diagnosed patients with Acute Myeloid Leukemia (AML) of any risk group, 18 years of age or older
2- No prior therapy
3- Willing to continue treatment (induction) at TMH
Exclusion Criteria
1- Acute Promyelocytic Leukemia
2- Patients not willing to participate in the study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Induction related mortalityTimepoint: End of Induction that is 28 to 35 days
- Secondary Outcome Measures
Name Time Method Complete Remission RateTimepoint: End of Induction that is 28 to 35 days;Cost of treatmentTimepoint: End of Induction that is 28 to 35 days;Quality of LifeTimepoint: End of Induction that is 28 to 35 days;Time toxicity that is the number of days the patient is in contact with healthcareTimepoint: End of Induction that is 28 to 35 days